THURSDAY, NOVEMBER 15

07:30-08:30  Breakfast  
Crystal Ballroom Foyer

08:30-10:10  Educational Session: Genomics-Driven Clinical Trials  
Crystal Ballroom

Session Cochairs: Yoon-Koo Kang, University of Ulsan College of Medicine, Seoul, Korea, and Elaine R. Mardis, Nationwide Children’s Hospital, Columbus, OH, USA

08:30-08:55  Precision medicine in lung cancer: Prime time  
Myung-Ju Ahn, Sungkyunkwan University Samsung Medical Center, Seoul, Korea

08:55-09:20  The Umbrella Trial in GC: Understanding the disease through genomics  
Jeeyun Lee, Sungkyunkwan University Samsung Medical Center, Seoul, Korea

09:20-09:45  Tumor agnostic drug development: Revisiting the scorecard in 2018  
Alexander E. Drilon, Memorial Sloan Kettering Cancer Center, New York, NY, USA

09:45-10:10  Overview of genomic technologies  
Elaine R. Mardis

10:10-10:30  Break

10:30-11:20  Welcome and Opening Keynote Lecture  
Crystal Ballroom

Opening Keynote Lecture  
Precision medicine in lung cancer: Opportunities and challenges  
Waun Ki Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

11:20-13:00  Luncheon Symposia and Special Lecture  
Sessions will be held simultaneously

11:20-11:50  Luncheon Symposium 1  
Crystal Ballroom  
Presented by ONO Pharma Korea / Bristol-Myers Squibb  
Session Chair: Geon Kook Lee, National Cancer Center, Goyang, Korea  
Tumor mutational burden as a predictive biomarker in immuno-oncology: Implications for clinical practice and worldwide implementation  
Aurora Seminara, Bristol-Myers Squibb, Princeton, NJ, USA

11:20-12:00  Luncheon Symposium 2  
Emerald Room  
Presented by AstraZeneca  
Session Chair: Sang-We Kim, University of Ulsan College of Medicine, Seoul, Korea  
Optimal strategy to manage T790M mutant NSCLC patients: from diagnosis to treatment  
Hye Ryun Kim, Yonsei University College of Medicine, Seoul, Korea

11:20-12:00  Luncheon Symposium 3  
Sapphire Ballroom A  
Presented by Merck Korea  
Session Chair: Young Suk Park, Samsung Medical Center, Seoul, Korea  
Optimized treatment strategy in RASwt mCRC with recent precision medicine  
Myung Ah Lee, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:00-13:00| **Special Lecture 1: “Scientia potentia est”—NGS-based precision medicine**  
Crystal Ballroom  
*Session Chair: Yeul Hong Kim, Korea University College of Medicine, Seoul, Korea* |
| 12:00-12:15| **K-MASTER Program overview: Korean Precision Medicine Initiative**  
Yeul Hong Kim, Korea University College of Medicine, Seoul, Korea |
| 12:15-12:30| **QuIP TMB technical comparability study: The German approach**  
Jörg Maas, Qualitätssicherungs-Initiative Pathologie, Berlin, Germany |
| 12:30-13:00| **Discussion and Q&A: Regulatory considerations for NGS oncopanel development**  
Panelists: Yeul Hong Kim, Geon Kook Lee, Jörg Maas, and Aurora Seminara |
| 13:00-13:25| **Knowledge to practice using cancer genomics**  
Se-Hoon Lee, Samsung Medical Center, Seoul, Korea |
| 13:25-13:50| **Genomic and epigenomic profiles of Asian gastrointestinal malignancies**  
Patrick Tan |
| 13:50-14:15| **Identification of genomic features that can predict the response to chemotherapy using patient-derived xenograft models**  
Jong-Il Kim, Seoul National University College of Medicine, Seoul, Korea |
| 14:15-14:40| **Implementing cancer genomics into the diagnosis and treatment of pediatric cancer**  
Elaine R. Mardis, Nationwide Children’s Hospital, Columbus, OH, USA |
| 14:40-15:00| **Break** |
| 15:00-16:40| **Plenary Session 2: Precision Diagnostics: NGS-Based Cancer Panels**  
Crystal Ballroom  
*Session Cochair: Eun Sook Lee, National Cancer Center Korea, Goyang, Korea, and Thomas D. Brown, Swedish Cancer Institute, Seattle, WA, USA* |
| 15:00-15:25| **Current status of the Korean Cancer Precision Medicine Project, K-Master**  
Yeul Hong Kim, Korea University College of Medicine, Seoul, Korea |
| 15:25-15:50| **Impact of clinical NGS: Lessons from lung cancer**  
Jessica Jiyeong Lin, Massachusetts General Hospital Cancer Center, Boston, MA, USA |
| 15:50-16:15| **Updated results and new studies in the nationwide NGS-based new agent development**  
Atsushi Ohtsu, National Cancer Center Hospital East, Chiba, Japan |
| 16:40-17:10| **Spotlight on Proffered Papers Session 1**  
Crystal Ballroom  
*Session Cochair: Tae Won Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, and Jessica Jiyeong Lin, Massachusetts General Hospital Cancer Center, Boston, MA, USA* |
| 16:40-16:50| **Targeted sequencing analysis of pulmonary adenocarcinoma with multiple synchronous ground-glass/lepidic nodules**  
Eunhyang Park, Seoul National University Bundang Hospital, Seoul National University College Of Medicine, Seongnam, Korea |
| 16:50-17:00| **Mechanisms of gene fusion formation in bone and soft tissue tumors**  
Nathaniel Anderson, The Hospital for Sick Children, Toronto, ON, Canada |

*Short talk from proffered abstract*
17:00-17:10  TET1-mediated 5-hydroxymethylcytosine alteration in the pathogenesis of medulloblastoma*
Hyerim Kim, Emory University, Atlanta, GA, USA

17:15-19:30  Poster Session A and Reception
Sapphire Ballroom B

FRIDAY, NOVEMBER 16

07:30-08:30  Breakfast
Crystal Ballroom Foyer

08:30-10:10  Plenary Session 3: Liquid Biopsy
Crystal Ballroom

Session Co-chairs: Tae-You Kim, Seoul National University Hospital, Seoul, Korea, and Ryan Dittamore, Epic Sciences, San Diego, CA, USA

08:30-08:55  Monitoring treatment response and progression in cancer patients with circulating tumor DNA sequencing
Woong-Yang Park, Samsung Genome Institute, Seoul, Korea

08:55-09:20  Clinical validation of single CTC profiling as a predictive biomarker of treatment selection in mCRPC
Ryan Dittamore

09:20-09:45  Technology perspectives of liquid biopsy
Duhee Bang, Yonsei University, Seoul, Korea

09:45-10:10  Plasma circulating tumor DNA predicts therapy outcomes in advanced prostate cancer
Alexander W. Wyatt, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

10:10-10:40  Break

10:40-11:20  Keynote Lecture
Crystal Ballroom

10:40-10:45  Introduction
Tae-You Kim, Seoul National University Hospital, Seoul, Korea

10:45-11:20  Clinical trials in the era of precision medicine
Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Korea

11:20-13:00  Luncheon Symposia and Special Lecture
Sessions will be held simultaneously

11:20-12:00  Luncheon Symposium 4
Crystal Ballroom
Presented by Roche Korea

Session Chair: Ki Hyeong Lee, Chungbuk National University College of Medicine, Cheongju, Korea

Targeting VEGF in the era of cancer immunotherapy
Ji-Youn Han, National Cancer Center, Goyang, Korea

11:20-12:00  Luncheon Symposium 5
Emerald Room
Presented by Amgen Korea

Session Chair: Jin Seok Ahn, Samsung Medical Center, Seoul, Korea

RANKL inhibition as a treatment option in preventing skeletal-related events in cancer patients with bone metastases
Alison T. Stopeck, University of Arizona Cancer Center, Tucson, AZ, USA

11:20-12:00  Luncheon Symposium 6
Sapphire Ballroom A
Presented by Sanofi Genzyme

Session Chair: Jong Gwang Kim, Kyungpook National University School of Medicine, Daegu, Korea

Expanding the horizons in treatment of mCRC: How to choose the “right” second line
Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan

*Short talk from proffered abstract
12:10-13:00  Special Lecture 2  
Crystal Ballroom  

Session Chair: Jin-Hyoung Kang, College of Medicine, The Catholic University of Korea, Seoul, Korea  

Building a clinico-genomic database to inform cancer immunotherapy treatment  
Geoff Otto, Foundation Medicine, Cambridge, MA, USA  

13:00-14:40  Plenary Session 4: Novel Technologies  
Crystal Ballroom  

Session Co-chairs: Seock-Ah Im, Seoul National University Hospital, Seoul, Korea, and William C. Hahn, Dana-Farber Cancer Institute, Boston, MA, USA  

Computational inference of cancer dependencies in clinical samples  
Jung Kyoon Choi, KAIST, Daejeon, Korea  

Lineage plasticity in prostate cancer  
Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA  

Architecture of genomic rearrangements molding fusion oncogenes in lung adenocarcinomas  
Young Seok Ju, KAIST, Daejeon, Korea  

Defining a cancer dependencies map  
William C. Hahn  

13:14:00  Break  

15:00-15:25  Effective biomarker for immune-precision treatment of metastatic gastric cancer  
Sun Young Rha, Yonsei University College of Medicine, Seoul, Korea  

15:25-15:50  Comparative analysis of tumor-infiltrating T cells across multiple tumor indications  
Zemin Zhang  

15:50-16:15  Advancement in anti-PD-1 therapy: Prediction and combination  
Eui-Cheol Shin, KAIST, Daejeon, Korea  

16:15-16:40  Role of regulatory T cells in immuno-oncology  
Hiroyoshi Nishikawa, National Cancer Center, Chiba, Japan  

16:40-17:00  Spotlight on Proffered Papers Session 2  
Crystal Ballroom  

Session Co-chairs: Jeeyun Lee, Sungkyunkwan University Samsung Medical Center, Seoul, Korea, and Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, NY, USA  

Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy*  
Joo Sang Lee, Cancer Data Science Lab, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA  

Myeloid-derived suppressor cells impair the antitumor activity of PD-1 blockade in gastric cancer*  
Woosook Kim, Columbia University, New York, NY, USA  

17:00-17:10  Humanized N-cadherin monoclonal antibodies demonstrate efficacy in treatment of castration-resistant prostate cancer*  
Evelyn Kono, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA  

17:15-19:30  Poster Session B and Reception  
Sapphire Ballroom B  

*Short talk from proffered abstract
SATURDAY, NOVEMBER 17

07:30-08:30  Breakfast
Crystal Ballroom Foyer

08:30-10:10  Plenary Session 6: Novel Targets
Crystal Ballroom

Session Cochairs: Young-Joon Surh, Seoul National University College of Pharmacy, Seoul, Korea, and Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA

08:30-08:55  Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
Byoung Chul Cho, Yonsei University College of Medicine, Seoul, Korea

08:55-09:20  Targeting MAT2A in MTAP-deleted cancers
Katya Marjon, Agios Pharmaceuticals, Cambridge, MA, USA

09:20-09:45  Using organoids to model, detect, and treat cancer
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA, USA

09:45-10:10  Targeting DNA damage repair: PARP inhibitor and beyond
Seock-Ah Im, Seoul National University College of Medicine, Seoul, Korea

10:10-10:40  Break

10:40-12:20  Plenary Session 7: Epigenomics
Crystal Ballroom

Session Cochairs: Jin-Hyoung Kang, College of Medicine, The Catholic University of Korea, Seoul, Korea, and Patrick Trojer, Constellation Pharmaceuticals, Cambridge, MA, USA
14:00-15:25  **Plenary Session 8: Immunology: Technologies and Innovations**  
Crystal Ballroom  

**Session Cochairs:** Young-Joon Kim, Yonsei University, Seoul, Korea and Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY, USA

14:00-14:25  **Immune profiling of B lymphocytes in the era of cancer immunotherapy**  
Junho Chung, Seoul National University College of Medicine, Seoul, Korea

14:25-14:50  **CAR therapy: The CD19 paradigm and beyond**  
Michel Sadelain

14:50-15:15  **A personalized cancer vaccine targeting neoepitopes**  
Chang-Yuil Kang, Seoul National University College of Pharmacy, Seoul, Korea

15:15-15:25  **Multiplex three-dimensional imaging cytometry for mapping tumor immune microenvironment**  
Steve Seung-Young Lee, University of Illinois at Chicago, Chicago, IL, USA

15:25-15:30  **Closing Remarks**  
Crystal Ballroom  

Tae-You Kim, Seoul National University Hospital, Seoul, Korea  
Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA

*Short talk from proffered abstract*